Clinical Trials
138
Active:42
Completed:77
Trial Phases
5 Phases
Phase 1:24
Phase 2:25
Phase 3:39
+2 more phases
Drug Approvals
4
NMPA:4
Drug Approvals
Drospirenone and Ethinylestradiol Tablets
- Product Name
- 屈螺酮炔雌醇片
- Approval Number
- 国药准字HJ20210029
- Approval Date
- Apr 30, 2021
NMPA
Clinical Trials
Distribution across different clinical trial phases (103 trials with phase data)• Click on a phase to view related trials
Phase 3
39 (37.9%)Phase 2
25 (24.3%)Phase 1
24 (23.3%)Phase 4
9 (8.7%)Not Applicable
6 (5.8%)Effects of Fenofibrate on Gene Expression in Healthy Volunteers
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT01109758
- Locations
- 🇬🇧
Site 1, London, United Kingdom
A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: pioglitazone/rosiglitazone/placeboDrug: rosiglitazone/pioglitazone/placeboDrug: placebo/pioglitazone/rosiglitazoneDrug: pioglitazone/placebo/rosiglitazoneDrug: rosiglitazone/placebo/pioglitazoneDrug: placebo/rosiglitazone/pioglitazone
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2010-03-17
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01088594
- Locations
- 🇬🇧
S337.1.004 Site #, London, United Kingdom
Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion
Phase 1
Completed
- Conditions
- Pharmacology, Clinical
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT01044524
- Locations
- 🇳🇱
S334.1.004 - Site 1, Zuid-Laren, Netherlands
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00998933
- Locations
- 🇺🇸
Site 1, Miami Gardens, Florida, United States
Interaction Study SLV337/Simvastatin
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2009-09-09
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00924430
- Locations
- 🇬🇧
Site 1, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 18
- Next
News
No news found